MOLECULAR DOCKING, MOLECULAR DYNAMICS, AND IN SILICO TOXICITY PREDICTION STUDIES OF COUMARIN, N-OXALYLGLYCINE, ORGANOSELENIUM, ORGANOSULFUR, AND PYRIDINE DERIVATIVES AS HISTONE LYSINE DEMETHYLASE INHIBITORS

Authors

  • Fauzan Zein Muttaqin Department of Pharmacy, Bandung School of Pharmacy, Bandung, Indonesia.
  • Taufik Muhammad Fakih Department of Pharmacy, Bandung School of Pharmacy, Bandung, Indonesia.
  • Hubbi Nashrullah Muhammad Department of Pharmacy, Bandung School of Pharmacy, Bandung, Indonesia.

DOI:

https://doi.org/10.22159/ajpcr.2017.v10i12.19348

Keywords:

Histone lysine demethylase, Coumarine, N-oxalylglycine, Organoselenium, Organosulfur, Pyridine, Molecular docking, Molecular dynamics, Toxicity prediction

Abstract

Objective: Prostate cancer is the second most common cancer in men. One of the efforts in the treatment of prostate cancer is by inhibiting histone lysine demethylase. Derivative compounds of coumarine, N-oxalylglycine, organoselenium, organosulfur, and pyridine have been reported to be active against two types of histone lysine demethylase (KDM) enzymes, KDM4E and KDM5B. This study aims to study the interactions of these derivatives with KDM.

Methods: In this study, we performed computational studies, including molecular docking and molecular dynamics (MDs) simulations, and toxicity prediction, to assess the compounds' activities toward three other KDM enzymes, KDM1A, KDM4A, and KDM4C.

Results: Molecular docking simulations showed that a derivative compound of N-oxalylglycine, (R)-3-(4-[benzyloxy]phenyl)-2-(carboxyformamido) propanoic acid, and a derivative compound of pyridine, 3-(4-methoxybenzylamino)pyridine-2,4-dicarboxylic acid, has the highest affinity toward KDM. These results were confirmed in MDs studies which showed strong interactions at the active site of the five receptors. Toxicity prediction results show that the derivative compounds of coumarine, N-oxalylglycine, organoselenium, organosulfur, and pyridine are classified in category (high class), which suggests that the safety is not guaranteed, but is likely, not carcinogenic and nongenotoxic.

Conclusion: Several coumarin, N-oxalylglycine, organoselenium, organosulfur, and pyridine derivative compounds are predicted to be able to interact strongly with KDM. The results in this study are useful for further studies in the development of novel anticancer drugs that target KDM.

Downloads

Download data is not yet available.

References

Prostate Cancer Estimated Incidence, Mortality, and Prevalence Worldwide in 2012. Lyon: International Agency for Research on Cancer; c2016. Available from: https://www.iarc.fr/. [Last cited on 2016 Nov 26].

Purushothaman A, Kumar G, Gangadharan P, Roshni PR. A comparison of leuprolide acetate versus bilateral orchiectomy for patients with metastatic prostate cancer. Asian J Pharm Clin Res 2016;9(2):51-4.

Antony A, Joel JJ, Shetty J, Umar NF. Identification and analysis of adverse drug reactions associated with cancer chemotherapy in hospitalized patients. Int J Pharm Pharm Sci 2016;8(7):448-51.

Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer 2011;128(3):574-86.

Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, et al. Androgen receptor coactivator’s lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 2006;66(23):11341-7.

Kauffman EC, Robinson BD, Downes MJ, Powell LG, Lee MM, Scherr DS, et al. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog 2011;50(12):931-44.

Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y, et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012;21(4):473-87.

Wang LY, Guo W, Kevin K, Pochampalli M, Huch CL, Izumiya Y, et al. Histone demethylases. In: Kumar R, editor. Nuclear Signaling Pathways and Targeting Transcription in Cancer. California: Springer; 2014. p. 373-89.

Thakur RS, Ahirwar B. Ethno pharmacological evaluation of medicinal plants for cytotoxicity against various cancer cell lines. Int J Pharm PharmSci 2017;9(5):198-202.

Sayegh J, Cao J, Zou MR, Morales A, Blair LP, Norcia M, et al. Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J Biol Chem 2013;288(13):9408-17.

Kawamura A, Tumber A, Rose NR, King ON, Daniel M, Oppermann U, et al. Development of homogeneous luminescence assays for histone demethylase catalysis and binding. Anal Biochem 2010;404(1):86-93.

Gurula H, Loganathan T, Vashum Y, Pannerselvam S, Vetrivel U, Samuel S. In silico screening of potent PPR-Gamma agonists among natural anticancer compounds of Indian origin. Asian J Pharm Clin Res 2016;4:320-24.

Khan F, Bafna S, Gupta T, Emerson AI. Virtual screening of potential inhibitors from herbs for the treatment of breast cancer. Asian J Pharm Clin Res 2017;4:62-7.

Palani M, Natesan K, Vaiyapuri M. Computational studies on different types of apoptotic proteins docked with a dietary flavonoid eriodictyol in colon cancer. Asian J Pharm Clin Res 2017;10(1):223-6.

Ulfa DM, Arsianti A, Radji M. In silico docking studies of gallic acid structural analogs as BCL-XL inhibitor in cancer. Asian J Pharm Clin Res 2017;4:119-22.

Berendsen HJ, Postma JP, Gunsteren WF, DiNola A, Haak JR. Molecular dynamics with coupling to an external bath. J Chem Phys 1984;81:3684-90.

Darden T, York D, Pedersen L. Particle mesh Ewald: An N Log (N) method for Ewald sums in large systems. J Chem Phys 1993;98(12):10089-2.

Published

01-12-2017

How to Cite

Muttaqin, F. Z., T. M. Fakih, and H. N. Muhammad. “MOLECULAR DOCKING, MOLECULAR DYNAMICS, AND IN SILICO TOXICITY PREDICTION STUDIES OF COUMARIN, N-OXALYLGLYCINE, ORGANOSELENIUM, ORGANOSULFUR, AND PYRIDINE DERIVATIVES AS HISTONE LYSINE DEMETHYLASE INHIBITORS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 10, no. 12, Dec. 2017, pp. 212-5, doi:10.22159/ajpcr.2017.v10i12.19348.

Issue

Section

Original Article(s)